Immunoglobulin G1 (fc Domain-containing Fragment) Fusion Protein With Peptide (synthetic Linker) Fusion Protein With Interleukin 2 (synthetic Human Mutein) Uses, Dosage, Side Effects and more
Immunoglobulin G1 (fc Domain-containing Fragment) Fusion Protein With Peptide (synthetic Linker) Fusion Protein With Interleukin 2 (synthetic Human Mutein) is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease).
| Attribute | Details |
|---|---|
| Trade Name | Immunoglobulin G1 (fc Domain-containing Fragment) Fusion Protein With Peptide (synthetic Linker) Fusion Protein With Interleukin 2 (synthetic Human Mutein) |
| Generic | Efavaleukin alfa |
| Efavaleukin alfa Other Names | Efavaleukin alfa, Fc il-2 mutein fusion protein (amg-592), Immunoglobulin g1 (fc domain-containing fragment) fusion protein with peptide (synthetic linker) fusion protein with interleukin 2 (synthetic human mutein), dimer |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
